Literature DB >> 21712934

Adverse drug reaction and causality assessment scales.

Syed Ahmed Zaki1.   

Abstract

Entities:  

Year:  2011        PMID: 21712934      PMCID: PMC3109846          DOI: 10.4103/0970-2113.80343

Source DB:  PubMed          Journal:  Lung India        ISSN: 0970-2113


× No keyword cloud information.
Sir, I read with interest the articles by Gupta et al and Gulati et al on adverse drug reactions of antituberculous drugs.[12] I would like to make the following comments. Adverse drug reactions (ADRs) are a major cause of morbidity, hospital admission, and even death. Hence it is essential to recognise ADRs and to establish a causal relationship between the drug and the adverse event. It is desirable that ADRs should be objectively assessed and presented based on an acceptable “Probability Scale.” Many causality methods have been proposed to assess the relationship between a drug and an adverse event in a given patient, ranging from short questionnaires to comprehensive algorithms. The idea of creating a standardized assessment for the relationship-likelihood of case reports of suspected ADRs was in the hope that this would, in a structured way, lead to a reliable reproducible measurement of causality. The causality assessment system proposed by the World Health Organization Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre (WHO–UMC), and the Naranjo Probability Scale are the generally accepted and most widely used methods for causality assessment in clinical practice as they offer a simple methodology.[34] The above scales are structured, transparent, consistent, and easy to apply assessment methods. Table 1 summarizes the “Naranjo ADR Probability Scale,” which has gained popularity among clinicians because of its simplicity.[3] The WHO–UMC causality system takes into account the clinical-pharmacologic aspects, whereas previous knowledge of the ADR plays a less prominent role. Table 2 summarizes the WHO–UMC Probability Scale.[4]
Table 1

Naranjo ADR probability scale—items and score

QuestionYesNoDon’t know
Are there previous conclusion reports on this reaction?+100
Did the adverse event appear after the suspect drug was administered?+2–10
Did the AR improve when the drug was discontinued or a specific antagonist was administered?+100
Did the AR reappear when drug was re-administered?+2–10
Are there alternate causes [other than the drug] that could solely have caused the reaction?–1+20
Did the reaction reappear when a placebo was given?–1+10
Was the drug detected in the blood [or other fluids] in a concentration known to be toxic?+100
Was the reaction more severe when the dose was increased or less severe when the dose was decreased?+100
Did the patient have a similar reaction to the same or similar drugs in any previous exposure?+100
Was the adverse event confirmed by objective evidence?+100

Scoring for Naranjo algorithm: >9 = definite ADR; 5–8 = probable ADR; 1–4 = possible ADR; 0 = doubtful ADR.

Table 2

WHO–UMC causality categories

Causality termAssessment criteria (all points should be reasonably complied)
Certain

Event or laboratory test abnormality, with plausible time relationship to drug intake

Cannot be explained by disease or other drugs

Response to withdrawal plausible (pharmacologically, pathologically)

Event definitive pharmacologically or phenomenologically (ie, an objective and specific medical disorder or a recognized pharmacologic phenomenon)

Rechallenge satisfactory, if necessary

Probable/likely

Event or laboratory test abnormality, with reasonable time relationship to drug intake

Unlikely to be attributed to disease or other drugs

Response to withdrawal clinically reasonable

Rechallenge not required

Possible

Event or laboratory test abnormality, with reasonable time relationship to drug intake

Could also be explained by disease or other drugs

Information on drug withdrawal may be lacking or unclear

Unlikely

Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable (but not impossible)

Disease or other drugs provide plausible explanation

Conditional/unclassified

Event or laboratory test abnormality

More data for proper assessment needed, or

Additional data under examination

Unassessable/unclassifiable

Report suggesting an adverse reaction

Cannot be judged because information is insufficient or contradictory

Data cannot be supplemented or verified

Naranjo ADR probability scale—items and score Scoring for Naranjo algorithm: >9 = definite ADR; 5–8 = probable ADR; 1–4 = possible ADR; 0 = doubtful ADR. WHO–UMC causality categories Event or laboratory test abnormality, with plausible time relationship to drug intake Cannot be explained by disease or other drugs Response to withdrawal plausible (pharmacologically, pathologically) Event definitive pharmacologically or phenomenologically (ie, an objective and specific medical disorder or a recognized pharmacologic phenomenon) Rechallenge satisfactory, if necessary Event or laboratory test abnormality, with reasonable time relationship to drug intake Unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not required Event or laboratory test abnormality, with reasonable time relationship to drug intake Could also be explained by disease or other drugs Information on drug withdrawal may be lacking or unclear Event or laboratory test abnormality, with a time to drug intake that makes a relationship improbable (but not impossible) Disease or other drugs provide plausible explanation Event or laboratory test abnormality More data for proper assessment needed, or Additional data under examination Report suggesting an adverse reaction Cannot be judged because information is insufficient or contradictory Data cannot be supplemented or verified I humbly request the Editors that Lung India should use either of the above two scales while reviewing articles related to ADRs.
  3 in total

1.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

2.  Isoniazid-induced alopecia.

Authors:  K B Gupta; V Kumar; S Vishvkarma; R Shandily
Journal:  Lung India       Date:  2011-01

3.  Erythema multiforme due to antitubercular drugs.

Authors:  Sameer Gulati; H P Paljor; Rohit Mahajan; Pankaj Goel
Journal:  Lung India       Date:  2011-01
  3 in total
  37 in total

1.  Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies.

Authors:  Wei-Ti Chen; Ching-Chi Chi
Journal:  Br J Clin Pharmacol       Date:  2019-07-07       Impact factor: 4.335

2.  Agreement Among Different Scales for Causality Assessment in Drug-Induced Liver Injury.

Authors:  Saibal Das; Sapan K Behera; Alphienes S Xavier; Srinivas Velupula; Steven A Dkhar; Sandhiya Selvarajan
Journal:  Clin Drug Investig       Date:  2018-03       Impact factor: 2.859

Review 3.  Risk factors for adverse drug reactions in pediatric inpatients: a systematic review.

Authors:  Paulo Henrique Santos Andrade; Adriano da Silva Santos; Carlos Adriano Santos Souza; Iza Maria Fraga Lobo; Wellington Barros da Silva
Journal:  Ther Adv Drug Saf       Date:  2017-04-25

4.  Risperidone Induced Granulomatous Mastitis Secondary to Hyperprolactinemia in a Non-Pregnant Woman-A Rare Case Report in a Bipolar Disorder.

Authors:  Sadhana Holla; M B Amberkar; Avinash Kamath; Meena Kumari Kamalkishore; Balaji Ommurugan
Journal:  J Clin Diagn Res       Date:  2017-01-01

5.  Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report.

Authors:  Gangaparameswari Soundarrajan; Bharti Chogtu; Vybhava Krishna; Avinash Kamath G; Manisha Murugesan
Journal:  Psychopharmacol Bull       Date:  2019-02-15

6.  Zolpidem induced hyponatremia: a case report.

Authors:  Shanmuga Priya S; Britto Dl; Saravanan T
Journal:  J Clin Diagn Res       Date:  2014-09-20

7.  A case of probable labetalol induced hyperkalaemia in pre-eclampsia.

Authors:  Binny Thomas; P V Abdul Rouf; Wessam El Kassem; Moza Al Hail; Derek Stewart; Asma Tharannum; Afif Ahmed; Muna Al Saadi
Journal:  Int J Clin Pharm       Date:  2014-11-05

8.  Vancomycin Use in a Paediatric Intensive Care Unit of a Tertiary Care Hospital.

Authors:  Kannan Sridharan; Amal Al-Daylami; Reema Ajjawi; Husain Am Al Ajooz
Journal:  Paediatr Drugs       Date:  2019-08       Impact factor: 3.022

9.  Incidence of angiotensin-converting enzyme inhibitor-induced cough in a Malaysian public primary care clinic: A retrospective cohort study.

Authors:  Hou Chan Loo; Fairuz Osman; Siew Lee Ho; Sing Yee An; Yim Mei Au Yong; Ee Ming Khoo
Journal:  Malays Fam Physician       Date:  2022-03-22

10.  Severe liver and renal injuries following cerebral angiography: late life-threatening complications of non-ionic contrast medium administration.

Authors:  Paulo Sergio Lucas da Silva; Emerson Yukio Kubo; Marcelo Cunio Machado Fonseca
Journal:  Childs Nerv Syst       Date:  2015-08-19       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.